MoonLake Immunotherapeutics is followed by a fragmented group of sell-side analysts whose views diverge sharply. Across major aggregators, the average analyst price target clusters between roughly $28 and $31; the $30 central target used here is the rounded arithmetic mean of the most recent verified targets rather than any single firm's published "consensus." The underlying range is extraordinarily wide, from approximately $6 on the cautious end to $57 on the bullish end.
Bullish targets sit well above the stock price. Chardan Capital initiated coverage with a Buy rating and a $57 target in early November 2026, while H.C. Wainwright has reiterated a $50 target. Leerink Partners, Wedbush, BTIG, Clear Street, and Needham cluster in the $30 to $34 range. The bullish thesis rests on sonelokimab's strong Week 52 efficacy data in the Phase 3 VELA trial and a path toward regulatory filing. Cautious voices are meaningful, however: Goldman Sachs carries a Sell rating with a target around $12, and Stifel holds at $19, citing competitive and commercial concerns. This is not a tightly aligned "analyst consensus" but a genuinely divided debate.
MLTX shares have recently traded near $12.50, toward the lower end of a 52-week range of roughly $9.46 to $23.29, with a market capitalization near $1.1 billion. Reaching $30 from $12.50 would require an advance of about 140%, which must be characterized as a very large move. For context, the stock's own 52-week high is still well below the target.
The plausible path is binary and clinical-stage dependent. MoonLake does not yet report product revenue, so valuation hinges on the progress of its lead candidate, sonelokimab, a Nanobody-based therapy that inhibits IL-17A and IL-17F. Positive Week 52 data showing a 67% HiSCR75 response rate in hidradenitis suppurativa, an FDA meeting that Clear Street described as supporting a "best-in-class" label, and an expected 2026 biologics license application (BLA) provide a fundamental case for a substantially higher valuation if the program continues to deliver.
From a technical standpoint, the stock's 52-week high near $23.29 stands as a meaningful resistance level, well below the $30 target. The 200-day moving average, near $16.35, also sits overhead as a potential supply zone on any recovery. On the downside, the 52-week low near $9.46 represents the most durable support level. The stock currently trades near its 50-day moving average around $12, suggesting the shares are consolidating after a sharp de-rating from earlier highs. Rounded psychological levels of $10, $15, $20, and $25 may also influence trading behavior.
Analyst price targets typically reflect a roughly 12-month research horizon, though for a clinical-stage company the path is driven more by events than by a calendar. Investors should monitor the timing and acceptance of the BLA filing, any additional efficacy or safety data for sonelokimab in hidradenitis suppurativa and psoriatic arthritis, quarterly cash burn and runway updates, competitive product launches, and analyst rating or target revisions. Regulatory decisions from the FDA will be the single most consequential catalyst for whether the stock can re-rate toward the $30 level.
I've found Tickeron's AI Daily Buy/Sell Signals helpful for tracking how market conditions and technical factors are evolving for names like MLTX. The system generates Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis, which can help identify opportunities and monitor positions more efficiently than manual review alone. In volatile clinical-stage names, these signals provide an additional layer of insight alongside fundamental developments.
Can MoonLake Immunotherapeutics reach $30? The target, derived from the mean of current analyst price targets, sits roughly 140% above the recent price and would require a very large re-rating. The bull case is grounded in encouraging clinical data, a de-risked regulatory path, and substantial peak-sales potential for sonelokimab. The bear case is equally real, anchored in a crowded IL-17 market, a prior Phase 3 miss, and a Sell rating near $12 from Goldman Sachs. The outcome will likely be decided by regulatory and clinical events rather than valuation alone, and neither the $30 level nor any other figure should be treated as a guarantee. Investors should focus on the BLA timeline, competitive developments, and the company's cash runway as the key variables between here and the target.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The 10-day moving average for MLTX crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 19 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MLTX's RSI Indicator exited the oversold zone, 10 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MLTX as a result. In 81 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for MLTX just turned positive on October 20, 2026. Looking at past instances where MLTX's MACD turned positive, the stock continued to rise in 46 of 53 cases over the following month. The odds of a continued upward trend are 87%.
MLTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +16.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 162 of 181 cases where MLTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
MLTX broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.292) is normal, around the industry mean (3.498). P/E Ratio (-3.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology